“Proteomics give us a much more direct prediction of protein activity,” said Antonio Iavarone, MD, deputy director at Sylvester and the study’s lead author. “We hope this analysis can be seamlessly translated into the clinic as a next-generation precision therapy for this very challenging disease and other resistant cancers as well.”